RevenueNet IncomeP/EP/SEBITDividendStocksMarket capitalizationDebtLiabilitiesEquityAAQSEmployeesROEROAROCE
GC Biopharma Stock

GC Biopharma Debt 2024

GC Biopharma Debt

674,315.75 KRW

Ticker

006280.KS

ISIN

KR7006280002

In 2024, GC Biopharma's total debt was 674,315.75 KRW, a 24.62% change from the 541,110.44 KRW total debt recorded in the previous year.

GC Biopharma Aktienanalyse

What does GC Biopharma do?

GC Biopharma ist eines der beliebtesten Unternehmen auf Eulerpool.com.

Debt Details

Understanding GC Biopharma's Debt Structure

GC Biopharma's total debt refers to the cumulative financial obligations the company owes to external parties. This can include short-term and long-term borrowings, bonds, loans, and other financial instruments. Assessing the company's debt levels is crucial for evaluating its financial health, risk profile, and ability to fund operations and expansions.

Year-to-Year Comparison

Analyzing GC Biopharma's debt structure over the years provides insights into the firm’s financial strategy and stability. A reduction in debt can indicate financial strength and operational efficiency, while an increase may signal growth investments or potential financial challenges ahead.

Impact on Investments

Investors pay close attention to GC Biopharma’s debt levels as they can influence the company’s risk and return profiles. Excessive debt can lead to financial strain, while moderate and well-managed debt can be a catalyst for growth and expansion, making it a critical aspect of investment evaluations.

Interpreting Debt Fluctuations

Shifts in GC Biopharma’s debt levels can be attributed to various operational and strategic factors. An increase in debt might be geared towards funding expansion projects or enhancing operational capacity, while a decrease may indicate profit realizations or an approach to minimize financial risk and leverage.

Frequently Asked Questions about GC Biopharma stock

What is the debt of GC Biopharma this year?

GC Biopharma has a debt level of 674,315.75 KRW this year.

What was the debt of GC Biopharma compared to the previous year?

The debt of GC Biopharma has increased by 24.62% compared to the previous year increased.

What are the consequences of high debt for investors in GC Biopharma?

High debt can pose a risk for investors of GC Biopharma, as it can weaken the company's financial position and hinder its ability to fulfill its obligations.

What are the consequences of low debt for investors of GC Biopharma?

Low debt means that GC Biopharma has a strong financial position and is able to fulfill its obligations without overburdening its finances.

How does an increase in debt from GC Biopharma affect the company?

An increase in debt of GC Biopharma can adversely affect the financial condition of the company and result in a higher burden on its finances.

How does a reduction of debt of GC Biopharma affect the company?

A reduction in debt of GC Biopharma can strengthen the company's financial position and improve its ability to meet its financial obligations.

What are some factors that influence the debt of GC Biopharma?

Some factors that can influence the debt of GC Biopharma include investments, acquisitions, operating costs, and revenue development.

Why are the debts of GC Biopharma so important for investors?

The debts of GC Biopharma are important for investors as they serve as an indicator of the company's financial stability. It provides investors with information on how the company fulfills its financial obligations.

What strategic measures can GC Biopharma take to change the debt?

To change the debt, GC Biopharma can take measures such as cost savings, increasing revenue, selling assets, making investments, or forming partnerships. It is important for the company to conduct a thorough review of its financial situation to determine the best strategic actions to change its debt.

How much dividend does GC Biopharma pay?

Over the past 12 months, GC Biopharma paid a dividend of 1,500 KRW . This corresponds to a dividend yield of about 1.11 %. For the coming 12 months, GC Biopharma is expected to pay a dividend of 1,554.78 KRW.

What is the dividend yield of GC Biopharma?

The current dividend yield of GC Biopharma is 1.11 %.

When does GC Biopharma pay dividends?

GC Biopharma pays a quarterly dividend. This is distributed in the months of January, January, January, January.

How secure is the dividend of GC Biopharma?

GC Biopharma paid dividends every year for the past 22 years.

What is the dividend of GC Biopharma?

For the upcoming 12 months, dividends amounting to 1,554.78 KRW are expected. This corresponds to a dividend yield of 1.15 %.

In which sector is GC Biopharma located?

GC Biopharma is assigned to the 'Health' sector.

Wann musste ich die Aktien von GC Biopharma kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of GC Biopharma from 5/1/2024 amounting to 1,500 KRW, you needed to have the stock in your portfolio before the ex-date on 12/27/2023.

When did GC Biopharma pay the last dividend?

The last dividend was paid out on 5/1/2024.

What was the dividend of GC Biopharma in the year 2023?

In the year 2023, GC Biopharma distributed 1,750 KRW as dividends.

In which currency does GC Biopharma pay out the dividend?

The dividends of GC Biopharma are distributed in KRW.

Stock savings plans offer an attractive way for investors to build wealth over the long term. One of the main advantages is the so-called cost-average effect: by regularly investing a fixed amount in stocks or stock funds, you automatically buy more shares when prices are low, and fewer when they are high. This can lead to a more favorable average price per share over time. In addition, stock savings plans allow small investors access to expensive stocks, as they can participate with small amounts. Regular investment also promotes a disciplined investment strategy and helps to avoid emotional decisions, such as impulsive buying or selling. Furthermore, investors benefit from the potential appreciation of the stocks as well as from dividend distributions, which can be reinvested, enhancing the compounding effect and thus the growth of the invested capital.

Andere Kennzahlen von GC Biopharma

Our stock analysis for GC Biopharma Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of GC Biopharma Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.